SCHEMBL2269795

SCHEMBL2269795

O=C(O)c1ccc(CCc2ccccc2)cc1NC(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 2/20 0.55
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
RECQL P46063 1/20 0.51
BLM P54132 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
GRIK1 P39086 2/20 0.47
PBRM1 Q86U86 1/20 0.47
PLK1 P53350 1/20 0.46
HCAR2 Q8TDS4 3/20 0.46
ALOX15 P16050 1/20 0.44
ACLY P53396 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
TRPM4 Q8TD43 1/20 0.44
SCN5A Q14524 1/20 0.44
SCN2A Q99250 1/20 0.44
ITGB1 P05556 1/20 0.43
ITGA4 P13612 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275852 0.88 MEN1 (0.55) SLC16A3MEN1KMT2ARECQLBLM
SCHEMBL2273479 0.85 NPC1 (0.53) MEN1KMT2ARECQLBLMTDP1
SCHEMBL2275549 0.84 SLC16A3 (0.43) SLC16A3MEN1KMT2APLK1ALOX15
SCHEMBL2364731 0.84 SRC (0.58) MEN1KMT2ARECQLBLMTDP1
SCHEMBL2273138 0.82 GRIK1 (0.59) SLC16A3MEN1KMT2ATDP1GRIK1
SCHEMBL2270227 0.82 SLC16A3 (0.58) SLC16A3MEN1KMT2ARECQLBLM
SCHEMBL2275929 0.82 KMT2A (0.62) MEN1KMT2ATDP1GRIK1PLK1
SCHEMBL2274700 0.82 MEN1 (0.55) MEN1KMT2ATDP1GRIK1PLK1
SCHEMBL2271168 0.82 ACLY (0.67) MEN1KMT2ARECQLBLMTDP1
SCHEMBL4213736 0.82 MEN1 (0.56) MEN1KMT2ARECQLBLMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SLC16A3 380/4885MEN1 3105/4885KMT2A 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.